Patent classifications
C07C255/55
COMPOUND, POLYMERIZABLE COMPOSITION, OPTICALLY ANISOTROPIC FILM, OPTICAL FILM, POLARIZING PLATE, AND IMAGE DISPLAY DEVICE
A compound that is suitably used for formation of an optically anisotropic film having excellent reverse wavelength dispersibility and moisture-heat resistance; a polymerizable composition; an optically anisotropic film; an optical film; a polarizing plate; and an image display device. The present invention relates to a compound represented by Formula (I-1) P.sup.1-SP.sup.1-Ar.sup.1-Mes-Ar.sup.2-SP.sup.2-P.sup.2 (I-1).
LABILE ESTERS OF AGROCHEMICALS FOR CONTROLLED RELEASE AND REDUCTION OF OFF-SITE MOVEMENT
The present invention relates to esters of carboxylic acid agrochemicals comprising a labile protecting group and having formula (I). Certain of the esters of carboxylic acid agrochemicals do not undergo hydrolysis to a significant degree in the dark, but are cleaved to regenerate the parent carboxylic acid agrochemical when exposed to light. Others of the esters of carboxylic acid agrochemicals undergo hydrolysis under both light and dark conditions. The present invention further relates to methods for the controlled release of a carboxylic acid agrochemicals, and to methods of controlling unwanted plants comprising applying to the unwanted plants an ester of a carboxylic acid agrochemical.
LABILE ESTERS OF AGROCHEMICALS FOR CONTROLLED RELEASE AND REDUCTION OF OFF-SITE MOVEMENT
The present invention relates to esters of carboxylic acid agrochemicals comprising a labile protecting group and having formula (I). Certain of the esters of carboxylic acid agrochemicals do not undergo hydrolysis to a significant degree in the dark, but are cleaved to regenerate the parent carboxylic acid agrochemical when exposed to light. Others of the esters of carboxylic acid agrochemicals undergo hydrolysis under both light and dark conditions. The present invention further relates to methods for the controlled release of a carboxylic acid agrochemicals, and to methods of controlling unwanted plants comprising applying to the unwanted plants an ester of a carboxylic acid agrochemical.
Reactive mesogens
The invention relates to reactive mesogens (RMs) comprising a terphenyl group, to mixtures and formulations comprising them, to polymers obtained form such RMs and RM mixtures, and the use of the RMs, RM mixtures and polymers in optical or electrooptical components or devices, like optical retardation films for liquid crystal displays (LCDs).
Reactive mesogens
The invention relates to reactive mesogens (RMs) comprising a terphenyl group, to mixtures and formulations comprising them, to polymers obtained form such RMs and RM mixtures, and the use of the RMs, RM mixtures and polymers in optical or electrooptical components or devices, like optical retardation films for liquid crystal displays (LCDs).
EBNA1 INHIBITORS AND THEIR METHOD OF USE
Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
EBNA1 INHIBITORS AND THEIR METHOD OF USE
Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
Fullerene derivative, organic solar cell using same, and manufacturing method thereof
The present specification relates to a fullerene derivative, an organic solar cell including the same, and a fabricating method thereof.
Fullerene derivative, organic solar cell using same, and manufacturing method thereof
The present specification relates to a fullerene derivative, an organic solar cell including the same, and a fabricating method thereof.
LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, COMPOSITE MATERIAL WITH ENCAPSULATED LIQUID CRYSTAL, AND LIQUID CRYSTAL DISPLAY DEVICE USING SAME
Shown is a bimesogenic compound having high solubility in a liquid crystal compound, a liquid crystal composition, a chiral dopant, an additive including an antioxidant or an ultraviolet light absorber, and a polymerizable liquid crystal compound, each of which is used in other bimesogenic compounds or a liquid crystal display device, while maintaining desired physical properties.
A compound is represented by formula (1), a liquid crystal composition contains the compound, conjugate fibers with an encapsulated liquid crystal obtained from the liquid crystal composition, and a liquid crystal display device is obtained from the conjugate fibers with the encapsulated liquid crystal.
MG.sup.1-Z.sup.a-Sp-Z.sup.b-MG.sup.2(1)